Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Cash & Equivalents (2020 - 2025)

Pulse Biosciences (PLSE) has 6 years of Cash & Equivalents data on record, last reported at $80.7 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 31.6% year-over-year to $80.7 million; the TTM value through Dec 2025 reached $80.7 million, down 31.6%, while the annual FY2025 figure was $80.7 million, 31.6% down from the prior year.
  • Cash & Equivalents reached $80.7 million in Q4 2025 per PLSE's latest filing, down from $95.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $119.3 million in Q1 2025 and bottomed at $12.7 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $64.2 million, with a median of $54.1 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 494.06% in 2021, then plummeted 35.49% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $44.4 million in 2021, then skyrocketed by 37.81% to $61.1 million in 2022, then tumbled by 32.64% to $41.2 million in 2023, then soared by 186.61% to $118.0 million in 2024, then tumbled by 31.6% to $80.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $80.7 million in Q4 2025, $95.2 million in Q3 2025, and $106.3 million in Q2 2025.